Efficacy of intralesional corticosteroid injections for scalp vitiligo: An effective therapeutic option
The Journal of Dermatology · 2023
DOI: 10.1111/1346-8138.16911 ↗Kurz gefasst
Leserbrief in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Tianjing Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Vitiligo, Hypopigmentation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Scalp vitiligo, one of the most common sites of vitiligo involvement, is often difficult to control. Considering the effectiveness of corticosteroid intralesional injections in alopecia areata (AA),1 we applied intralesional betamethasone to scalp vitiligo. Here, we retrospectively reviewed the efficacy in 10 patients with scalp vitiligo and reported the cases as follows. The study was approved by the institutional review board of the Dermatology Hospital of Southern Medical University. Ten patients with nonsegmental vitiligo were enrolled and informed consent was obtained from each patient. All of the patients mainly had scalp involvement and nine of them were treatment-resistant for at least 6 months, with NB-UVB, topical medications, and/or oral low-dose corticosteroids. Betamethasone (7-mg Diprospan ampule) was diluted to 1.75 mg/mL with lidocaine. The application was performed at the deep dermis level with points approximately 1 cm apart, and 0.1 mL of treatment was infused at each point.2 The patients were treated with betamethasone alone every 4 weeks, totaling three sessions, followed by 3- and 12-month follow-ups. The repigmentation rate was evaluated by a four-point grading scale of improvement: >90%, 50% to 90%, 10% to 49%, and 50% repigmentation). Four of the six patients achieved >90% repigmentation. Perfect repigmentation was achieved in two patients with autoimmune thyroid disease. The other four patients with leukotrichia had 1 year. At first glance, AA and vitiligo appear to be quite different. In fact, the two diseases have common genetic risk factors, and the immune cell populations and cytokines that drive each disease are also similar.3 Leukotrichia has traditionally been associated with segmental vitiligo. In scalp vitiligo, epidermal melanocytes are often the first target, and hair depigmentation may occur with disease progression, although hairs are usually spared in the early stages.4 The presence of leukotrichia is a poor prognosis for vitiligo repigmentation because of the depletion of the follicular melanocytic reservoir.5 Our research showed a higher repigmentation rate for patients without leukotrichia. Our study was specifically designed for patients with scalp vitiligo, which is known to show worse responses than face and body vitiligo. The results showed that scalp vitiligo treated as AA with corticosteroid injection alone had good efficacy. Considering the relatively low cost and minor adverse effects of betamethasone, we recommend intralesional injection of corticosteroids as a priority treatment option for scalp vitiligo. There was one incidence of reversible skin atrophy (Figure 1f). In addition, pain during injections is the main related adverse event. Topical application of lidocaine cream alleviated the adverse event. Our study was limited by its retrospective nature and small sample size. Novel prospective, randomized, controlled clinical studies are still needed in this issue. We have no funding source for this work. None declared. Reviewed and approved by Dermatology Hospital, Southern Medical University's institutional review board approval #2022139. Table S1 Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatology Hospital, Southern Medical University, Guangzhou, China.
ORCID-Profile: Guangpu Luo
Zitieren
APA
Wang, T., Zhao, P., Shi, X., Zhang, J., Ren, Y., & Luo, G. (2023). Efficacy of intralesional corticosteroid injections for scalp vitiligo: An effective therapeutic option. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16911
Vancouver
Wang T, Zhao P, Shi X, Zhang J, Ren Y, Luo G. Efficacy of intralesional corticosteroid injections for scalp vitiligo: An effective therapeutic option. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16911
BibTeX
@article{Wang2023,
author = {Wang, Tianjing and Zhao, Peizhen and Shi, Xiaowei and Zhang, Jialin and Ren, Yingying and Luo, Guangpu},
title = {Efficacy of intralesional corticosteroid injections for scalp vitiligo: An effective therapeutic option},
journal = {The Journal of Dermatology},
year = {2023},
doi = {10.1111/1346-8138.16911}
}
EUVIMED